Lipoprotein(a) Is an Independent Risk Factor for Peripheral Arterial Disease in Chinese Type 2 Diabetic Patients in Taiwan

Diabetes Care

Volumn 27, Issue 2, 2004, Pages 517-521

  Tseng, Chin Hsiao ^a,b,c  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGE; AGED; ANKLE; ANTHROPOMETRIC PARAMETERS; ARTERY DISEASE; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; GENDER; HUMAN; INSULIN TREATMENT; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; RISK FACTOR; SEX DIFFERENCE; SMOKING; TAIWAN; TRIACYLGLYCEROL BLOOD LEVEL; UNIVERSITY HOSPITAL;

ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD GLUCOSE; BLOOD PRESSURE; CHOLESTEROL; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; FEMALE; HUMANS; LIPIDS; LIPOPROTEIN(A); MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PERIPHERAL VASCULAR DISEASES; RISK FACTORS; SEX CHARACTERISTICS; TAIWAN;

EID: 0842311550     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.27.2.517     Document Type: Article

References (23)

1. Scanu AM: Lipoprotein(a) and the atherothrombotic process: mechanistic insights and clinical implications. Curr Atheroscler Rep 5:106-113, 2003
2. Rainwater DL, Kammerer CM: Lipoprotein Lp(a): effects of allelic variation at the LPA locus. J Exp Zool 282:54-61, 1998
3. Utermann G: The mysteries of lipoprotein(a). Science 246:904-910, 1989
4. Scanu AM, Lawn RM, Berg K: Lipoprotein(a) and atherosclerosis. Ann Int Med 115:209-218, 1991
5. Hunninghake DB, McGovern ME, Koren M, Brazg R, Murdock D, Weiss S, Pearson T: A dose-ranging study of a new, once-daily, dual-component drug product containing niacin extended-release and lovastatin. Clin Cardiol 26:112-118, 2003
6. Habib SS, Aslam M, Naveed AK, Sattar A: Lipoprotein(a) and glycemic control in Pakistani subjects with diabetes mellitus. J Pak Med Assoc 53:54-59, 2003
7. Ridker PM, Hennekens CH, Stampfer MJ: A prospective study of lipoprotein(a) and the risk of myocardial infarction. JAMA 270:2195-2199, 1993
8. Alfthan G, Pekkanen J, Jauhiainen M, Pitdaniemi J, Karvonen M, Tuomilehto J, Salonen JT, Ehnholm C: Relation of serum homocysteine and lipoprotein(a) concentrations to atherosclerotic disease in a prospective Finnish population based study. Atherosclerosis 106:9-19, 1994
9. Cantin B, DespresJP, Lamarche B, Moorjani S, Lupien PJ, Bogaty P, Bergeron J, Dagenais GR: Association of fibrinogen and lipoprotein(a) as a coronary heart disease risk factor in men (the Quebec Cardiovascular Study). Am J Cardiol 89:662-666, 2002
10. Schaefer EJ, Lamon-Fava S, Jenner JL, McNamara JR, Ordovas JM, Davis CE, Abolafia JM, Lippel K, Levy RI: Lipoprotein(a) levels and risk of coronary heart disease in men: the Lipid Research Clinics Coronary Primary Prevention Trial. JAMA 271:999-1003, 1994
11. Kostner GM, Avogaro P, Cazzolato G, Marth E, Bitolo-Bon G, Qunici GB: Lipoprotein(a) and the risk for myocardial infarction. Atherosclerosis 38:563-568, 1981
12. Saku K, Zhang B, Liu R, Shirai K, Arakawa K: Associations among serum lipoprotein(a) levels, apolipoprotein(a) phenotypes, and myocardial infarction in patients with extremely low and high levels of serum lipoprotein(a). Jpn Circ J 63:659-665, 1999
13. Zenker G, Koltringer P, Bone G, Niederkorn K, Pfeiffier K, Jurgens G: Lipoprotein(a) as a strong indicator for cerebrovascular disease. Stroke 17:942-945, 1986
14. Valentine RJ, Grayburn PA, Vega DL, Grundy SM: Lp(a) lipoprotein is an independent discriminating risk factor for premature peripheral atherosclerosis among white men. Arch Intern Med 154:801-806, 1994
15. Wollesen F, Dahlen G, Berglund L, Berne C: Peripheral atherosclerosis and serum lipoprotein(a) in diabetes. Diabetes Care 22:93-98, 1999
16. Chien KL, Lee YT, Sung FC, Su TC, Hsu HC, Lin RS: Lipoprotein (a) level in the population in Taiwan: relationship to sociodemographic and atherosclerotic risk factors. Atherosclerosis 143:267-273, 1999
17. Tseng CH, Chong CK, Chen CJ, Tai TY: Dose-response relationship between peripheral vascular disease and ingested inorganic arsenic among residents in blackfoot disease endemic villages in Taiwan. Atherosclerosis 120:125-133, 1996
18. Tseng CH, Chong CK, Chen CJ, Tai TY: Lipid profile and peripheral vascular disease in arseniasis-hyperendemic villages in Taiwan. Angiology 48:321-335, 1997
19. Tseng CH, Tseng CP: Lack of association between angiotensin-converting enzyme gene polymorphism and peripheral vascular disease in type 2 diabetic patients in Taiwan. Circ J 66:1014-1018, 2002
20. Guidelines Subcommittee: World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. J Hypertens 17:151-183, 1999
21. Tseng CH, Tai TY, Chong CK, Tseng CP, Lai MS, Lin BJ, Chiou HY, Hsueh YM, Hsu KH, Chen CJ: Long-term arsenic exposure and incidence of non-insulin-dependent diabetes mellitus: a cohort study in arseniasis-hyperendemic villages in Taiwan. Environ Health Perspect 108:847-851, 2000
22. Tseng CH: Body composition as a risk factor for coronary artery disease in Chinese type 2 diabetic patients in Taiwan. Circ J 67:479-484, 2003
23. Tseng CH, Chong CK, Lin BJ, Chen CJ, Tai TY: Atherosclerotic risk factors for peripheral vascular disease in non-insulin-dependent diabetic patients. J Formos Med Assoc 93:663-667, 1994